Oncology Medical News about cancer mortality;schizophrenia

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cancer mortality in patients with schizophrenia
Cancer, 06/30/09

Tran E et al. - In a study to explore the relationship between cancer mortality and schizophrenia, the results of the current study demonstrated an increased risk of mortality by cancer in pts with schizophrenia, especially for women from breast cancer and for men from lung cancer.

Methods

In 1993, a large prospective study was initiated in a cohort of 3470 pts with schizophrenia to examine cancer-related mortality and predictors.
Standardized mortality ratios (SMRs) were calculated, adjusting for age and sex relative to a representative sample of the French general population.

Results

During the 11-yr follow-up, 476 (14%) pts died; the mortality rate was nearly 4-fold higher than in the general population.
Cancer was the second most frequent cause of mortality (n=74), with a global SMR of 1.5.
For all cancers, the SMRs were 1.4 (not significant) for men and 1.9 for women.
For men, lung cancer was the most frequent localization (n=23; 50%), with an SMR of 2.2.
For women, breast cancer was the most frequent localization (n=11; 39%), with an SMR of 2.8.
In comparison with pts who did not die of cancer, there were 2 significant baseline predictors of death by lung cancer in the final logistic regression model: duration of smoking and age >38 yrs.

<< Previous
Prognostic significance of a pretreatment hematologic profile in...

Next >>
S-1 monotherapy in patients with advanced biliary tract cancer